High Mobility Group Box 1 contributes to Neuroinflammation and Central Sensitization After Nitroglycerin Stimulation...

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Chronic migraine (CM) is a debilitating neurological condition with complex underlying mechanisms.
• High Mobility Group Box 1 (HMGB1) is a protein implicated in inflammatory and pain pathways.
• The specific role of HMGB1 in the pathophysiology of CM requires further elucidation.

Purpose of the Study:

• To investigate the effect of HMGB1 in a preclinical model of chronic migraine.
• To determine the therapeutic potential of targeting HMGB1 for CM treatment.

Main Methods:

• A chronic migraine model was established using nitroglycerin (NTG) administration in rodents.
• HMGB1 protein expression and localization were assessed in the trigeminal nucleus caudalis (TNC) via Western blot and immunofluorescence.
• The efficacy of the HMGB1 inhibitor Glycyrrhizin was evaluated by measuring behavioral pain responses (paw withdrawal threshold) and key molecular markers (p-ERK, iNOS, CGRP) in the TNC.

Main Results:

• Nitroglycerin administration significantly increased HMGB1 levels in the TNC, with expression observed in neurons, microglia, and astrocytes.
• The CM model exhibited mechanical hypersensitivity, indicated by reduced paw withdrawal thresholds.
• Treatment with Glycyrrhizin significantly alleviated mechanical hypersensitivity and reduced the expression of p-ERK, iNOS, and CGRP in the TNC.

Conclusions:

• HMGB1 plays a critical role in mediating neuroinflammation and central sensitization associated with chronic migraine.
• Targeting HMGB1 presents a promising therapeutic strategy for mitigating chronic migraine.